Scientists probe Gut-Kidney link: can a common drug tame toxic bacteria?
NCT ID NCT05965440
Summary
This study aimed to understand how the kidney medication dapagliflozin might work by looking at its effects on gut bacteria. Researchers observed 50 non-diabetic patients with chronic kidney disease who were starting this drug as part of their normal care. They checked if 12 weeks of treatment changed the types of bacteria in the gut or the levels of waste products these bacteria make.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nephrology department, Hôpital Lyon Sud, Hospices Civils de Lyon
Lyon, France
Conditions
Explore the condition pages connected to this study.